Budget impact analysis of sFlt-1/PlGF ratio as prediction test in Italian women with suspected preeclampsia

Frusca, T.; Gervasi, Maria-Teresa; Paolini, Davide; Dionisi, Matteo; Ferrè, Francesca; Cetin, Irene

doi:10.1080/14767058.2016.1242122

Cited by 29 publications

(19 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the use of angiogenic factors in high‐risk populations (women who present with signs or symptoms of PE) may confer significant economic benefit . Various studies have suggested savings using the sFlt‐1/PlGF ratio of £334/patient (UK), £945/patient (UK); €670/patient (Italy), and using PlGF alone of £35 087/1000 patients (UK) …”

Section: Economic Modelling/potential Economic Impactmentioning

confidence: 99%

Angiogenic factors: potential to change clinical practice in pre‐eclampsia?

Cerdeira

Agrawal

Staff

et al. 2017

BJOG

View full text Add to dashboard Cite

Pre‐eclampsia is a complex disease with significant maternal and fetal morbidity and mortality. Its syndromic nature makes diagnosis and management difficult. The field is rapidly evolving with the definition of pre‐eclampsia being challenged by some organisations, with proteinuria no longer being essential in the presence of other features. In the last decade, angiogenic factors, in particular soluble fms‐like tyrosine kinase 1 (sFlt‐1), have emerged as important molecules in the pathogenesis of pre‐eclampsia. Here we review the most recent evidence regarding the potential of these factors as biomarkers and therapeutic targets for pre‐eclampsia.Tweetable abstractA review of angiogenic factors, sFlt‐1 and PlGF, in the diagnosis, prediction and management of pre‐eclampsia.

show abstract

Section: Economic Modelling/potential Economic Impactmentioning

confidence: 99%

Angiogenic factors: potential to change clinical practice in pre‐eclampsia?

Cerdeira

Agrawal

Staff

et al. 2017

BJOG

View full text Add to dashboard Cite

show abstract

“…In this study, we have shown a modest cost‐saving in comparison with other studies . Previous health economic studies of the implementation of PlGF testing in clinical care were based on hypothetical assumptions of reduction in resource use, with greater cost‐savings than we have presented in this analysis.…”

Section: Discussionmentioning

confidence: 58%

“…National guidelines have approved PlGF testing to rule out suspected pre‐eclampsia in the UK . Hypothetical economic models have found that PlGF‐based testing gives a cost‐saving of between £330 and £1032 per woman tested . These models have not examined trial data where use of PlGF has been incorporated into clinical care.…”

Section: Introductionmentioning

confidence: 99%

Placental growth factor testing for suspected pre‐eclampsia: a cost‐effectiveness analysis

Duhig

Seed

Myers

et al. 2019

BJOG

View full text Add to dashboard Cite

Objective To calculate the cost‐effectiveness of implementing PlGF testing alongside a clinical management algorithm in maternity services in the UK, compared with current standard care. Design Cost‐effectiveness analysis. Setting Eleven maternity units participating in the PARROT stepped‐wedge cluster‐randomised controlled trial. Population Women presenting with suspected pre‐eclampsia between 20+0 and 36+6 weeks’ gestation. Methods Monte Carlo simulation utilising resource use data and maternal adverse outcomes. Main outcome measures Cost per maternal adverse outcome prevented. Results Clinical care with PlGF testing costs less than current standard practice and resulted in fewer maternal adverse outcomes. There is a total cost‐saving of UK£149 per patient tested, when including the cost of the test. This represents a potential cost‐saving of UK£2,891,196 each year across the NHS in England. Conclusions Clinical care with PlGF testing is associated with the potential for cost‐savings per participant tested when compared with current practice via a reduction in outpatient attendances, and improves maternal outcomes. This economic analysis supports a role for implementation of PlGF testing in antenatal services for the assessment of women with suspected pre‐eclampsia. Tweetable abstract Placental growth factor testing for suspected pre‐eclampsia is cost‐saving and improves maternal outcomes.

show abstract

“…A reduction in overall healthcare costs by 28% was observed. In particular, test implementation reduced 69.5% of unnecessary hospitalizations [22]. A similar cost--effectiveness study of PE testing in UK was published.…”

Section: A Short-term Prediction and Exclusion Of Pementioning

confidence: 84%

How to identify pregnant women at risk of pre-eclampsia? — a review of the current literature

Kosińska-Kaczyńska¹,

Wielgoś²

2018

Ginekol Pol

View full text Add to dashboard Cite

Pre-eclampsia remains a major cause of poor perinatal outcome worldwide. As administering acetylsalicylic acid in a high risk population reduces the risk of PE, it is essential to identify women at risk of PE. Several algorithms for PE risk assessment have been developed. They include maternal factors combined with uterine artery pulsatility index, mean arterial pressure, serum pregnancy-associated plasma protein-A, placental growth factor, and serum soluble fms-like tyrosine kinase-1. Beside PE prophylaxis with acetylsalicylic acid, a proper management of women considered at a high risk of PE is essential. The sFlt-1:PlGF ratio between 20 and 34 + 6 weeks may be used to predict a short-term absence of PE or to predict the risk of PE diagnosis within 4 weeks and a significant shortening of the duration of pregnancy associated with it. The sFlt-1:PlGF ratio may be helpful in deciding about hospitalization or choosing the optimal time for corticosteroid administration in women at risk of PE. It may also help to reduce overall healthcare costs.

show abstract

Budget impact analysis of sFlt-1/PlGF ratio as prediction test in Italian women with suspected preeclampsia

Abstract: Introduction of sFlt-1/PlGF into hospital practice is cost-saving. Savings are generated primarily through improvement in diagnostic accuracy and reduction in unnecessary hospitalization for women before PE's onset.

Cited by 29 publications

References 17 publications

Angiogenic factors: potential to change clinical practice in pre‐eclampsia?

Angiogenic factors: potential to change clinical practice in pre‐eclampsia?

Placental growth factor testing for suspected pre‐eclampsia: a cost‐effectiveness analysis

How to identify pregnant women at risk of pre-eclampsia? — a review of the current literature

Contact Info

Product

Resources

About